<DOC>
	<DOCNO>NCT00760526</DOCNO>
	<brief_summary>The purpose study determine efficacy , tolerability , safety , effect quality life CGM child 4 less 10 year age type 1 diabetes .</brief_summary>
	<brief_title>Randomized Trial Assess Efficacy Safety Continuous Glucose Monitoring Children 4- &lt; 10 Years With T1DM</brief_title>
	<detailed_description>On day enrollment , hemoglobin A1c level obtain , potential subject evaluate study eligibility elicitation medical history performance physical examination study investigator . The subject return second visit 6 week enrollment visit . At visit , quality life questionnaire complete CGM sensor insert . The monitor blind glucose value see . The parent instructed insertion , calibration , care CGM . The subject return randomization visit 14 28 day blind CGM initiate . - Subjects compliant use CGM HGM randomize one two treatment group : CGM Group Control Group - For CGM Group , CGM , HGM , pump data ( applicable ) review change make diabetes management need . Parents taught use protocol-developed instruction change diabetes management use real time base CGM HGM data . Instructions download CGM HGM provide subject home computer . - For Control Group , HGM test strip provide . The HGM pump data ( applicable ) review change make diabetes management need . The blinded CGM data download review study personnel end first 6 month study . Parents taught use protocol-developed instruction make change diabetes management base HGM data . Both group follow-up visit 1,4,8,13,19 , 26 week ( +/- 1 week ) plus one contact visit ( include one phone contact second visit one week visit ) review diabetes management . - Both group download device data weekly basis ( subject computer ) . Subjects email access instruct email download data clinical center prior phone contact . - For group , visit , HGM pump ( applicable ) download CGM group , CGM download . In 13th 26th week , Control Group use blind CGM one week . The CGM Group continue use blind CGM . The Control Group return blind CGM clinic week . The data review personnel involve care subject determine additional blind sensor data need . The blinded data review study personnel management decision end first 6 month study . Following 26-week visit : - Subjects RT-CGM Group continue use CGM . - Subjects Control Group provide CGM sensor week blind use visit 1 week 4 week , phone contact first second week . - Both group visit 13 week 26 week</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . Clinical diagnosis type 1 diabetes use daily insulin therapy least twelve month 2 . Age &gt; 4.0 &lt; 10.0 year 3 . HbA1c &gt; = 7.0 % 4 . Current insulin regimen involve either use insulin pump multiple daily injection insulin ( least 3 shot per day ) last three month , plan switch modality insulin administration next 6 month ( e.g. , injection user switch pump , pump user switching injection , addition Lantus ( Glargine ) insulin ) 1 . Diabetes diagnose &lt; 6 month age 2 . Use medication oral/inhaled glucocorticoid judgment investigator affect wear sensor completion aspect protocol . 3 . The presence follow diseases another disease investigator believe contraindication participation protocol : Asthma treat systemic daily inhale corticosteroid last 6 month ( Intermittent treatment inhale corticosteroid exclude subject enrollment ) Cystic fibrosis ( Celiac disease adequately treat thyroid disease exclude subject enrollment ) 4 . Home use CGM past 6 month . 5 . Participation intervention study ( include psychological study ) past 6 week . 6 . Another member household participate study .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Continuous Glucose Monitor</keyword>
</DOC>